- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03892694
Mitattu kryosuihku potilaiden hoitoon, joilla on krooninen obstruktiivinen keuhkosairaus ja krooninen keuhkoputkentulehdus
Luonnehditaan mitatun kryosuihkeen vaikutusmekanismia kroonista obstruktiivista keuhkosairautta ja kroonista keuhkoputkentulehdusta sairastavien potilaiden hoitoon
To evaluate the relationship between airway structure and function in patients with chronic bronchitis treated with metered cryospray (MCS).
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
To identify the molecular and cellular targets of MCS treatment and determine the mechanistic relationship to airways remodelling in patients with chronic bronchitis. Phenotype, characterise and correlate clinical, physiological, histological and molecular parameters in patients with chronic bronchitis.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Groningen, Alankomaat
- University Medical Center Groningen
-
-
-
-
-
London, Yhdistynyt kuningaskunta, SW3 6NP
- The Royal Brompton Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
Each Subject must meet the following criteria to be enrolled in the study:
- Males and females ≥40 to <80 years of age.
- Subject is able to read, understand, and sign a written Informed Consent in order to participate in the study.
- Subject has a diagnosis of CB and COPD and has been symptomatic for a minimum of two years. (Chronic Bronchitis is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded).
- Subject is classified as having moderate or severe (GOLD stage 2-3) airflow obstruction defined by a post-bronchodilator of =>30% FEV1 to <80% predicted with a baseline FEV1/FVC of <0.70.
- Subject has a COPD assessment tool (CAT) score of ≥10.
- Subject is being treated according to current medically accepted treatment guidelines without successful resolution of chronic bronchitis and agrees to continue maintenance pulmonary/COPD medications (as defined per GOLD Standard for medications) for the duration of the study (subject must be on a regime of pulmonary medications for a minimum of 2 weeks prior to enrolment into the study).
- Smoking history of at least 10 pack years.
- Non-smoking for a minimum of 2 months prior to consent and agrees to continue not smoking for the duration of the study.
- Subject is able to adhere to and undergo 4 bronchoscopic procedures (5 for control subjects accepting cross over option), in the opinion of the investigator or per hospital guidelines.
- For women of childbearing potential: non-pregnant, non-lactating, and agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study.
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Subject has had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and/or steroids) within 6 weeks of initially planned study bronchoscopy.
- Diagnosis of asthma with an onset before 30 years of age.
- Subject has Alpha-1 antitrypsin deficiency.
- Subject has other origins of respiratory disease aside from chronic bronchitis and COPD.
- Subject is using e-cigarettes, vaping or taking any oral or inhaled substances not prescribed by a physician.
- Subject has untreatable or life-threatening arrhythmias, or history of inability to adequately oxygenate during a bronchoscopy, or has acute respiratory failure with hypercapnia.
- Subject has bullous emphysema characterized as large bullae >30 millimetres on HRCT; or subject has stenosis in the tracheobronchial system, tracheobronchomegaly, trachea-bronchomalacia, amyloidosis or cystic fibrosis.
- Subject has clinically significant bronchiectasis
- Subject has had a transplant procedure (any).
- Subject has a known mucosal tear, has undergone prior lung surgery such as pneumonectomy, lobectomy, bullectomy, or lung volume reduction surgery, bronchial thermoplasty, rheoplasty or cryotherapy.
- Subject has had a prior lung device procedure, including emphysema stent(s) implanted, lung coils, valves, lung denervation or other devices for emphysema.
- Subject is unable to temporarily discontinue use of anticoagulant therapy: warfarin, Coumadin, LMWH, heparin, clopidrogel (or equal).
- Subject has a serious medical condition, such as: uncontrolled coagulopathy or bleeding disorder, congestive heart failure, uncontrolled angina, myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes, uncontrolled hypertension, autoimmune disease or uncontrolled gastric reflux.
- Subject has or is receiving chemotherapy or active radiation therapy within the past 6 months or is expected to receive chemotherapy during participation in this study.
- Subject is or has been in another clinical investigational study within 6 weeks of enrolment.
- Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines).
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Treatment
MCS |
Bronchial metered cryospray using RejuvenAir® System. |
|
Huijausvertailija: Sham Control
Sham |
Sham control procedure |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Goblet cell density
Aikaikkuna: 6-months post treatment
|
Difference in change relative to baseline in goblet cell density per mm of basement membrane in endobronchial cryobiopsies at 6-months between treatment and sham-control groups |
6-months post treatment
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Histopathological examination of endobronchial cryobiopsies to determine Inflammatory cells and subtype density per mm of basement membrane
Aikaikkuna: 6-months post treatment
|
Proportion of inflammatory cells per mm of basement membrane for Neutrophil and Lymphocyte sequencing (RNA-seq) |
6-months post treatment
|
|
Histopathological examination of endobronchial cryobiopsies to determine epithelial cell density and area (including respiratory epithelial, goblet and basal cells) per mm of basement membrane
Aikaikkuna: 6-months post treatment
|
Proportion of epithelial cells per mm of basement membrane for Ciliary and Goblet cells |
6-months post treatment
|
|
Transcriptomics: Epithelial gene expression as measured by global gene expression sequencing (RNA-seq)
Aikaikkuna: 6-months post treatment
|
Transcriptomics: Epithelial gene expression as measured by global gene expression sequencing (RNA-seq) |
6-months post treatment
|
|
Pulmonary function tests including spirometry, body plethysmography and transfer factors KCO and TLCO
Aikaikkuna: 6-months post treatment
|
Pulmonary function tests including spirometry, body plethysmography and transfer factors KCO and TLCO |
6-months post treatment
|
|
Patient reported outcome measures including SGRQ, mMRC, CAT and Cough Questionnaires
Aikaikkuna: 6-months post treatment
|
Patient reported outcome measures including SGRQ, mMRC, CAT and Cough Questionnaires |
6-months post treatment
|
|
Health care utilisation assessments including number of respiratory exacerbations, emergency room visits, hospital and intensive care unit admissions related to respiratory adverse events
Aikaikkuna: 6-months post treatment
|
Health care utilisation assessments including number of respiratory exacerbations, emergency room visits, hospital and intensive care unit admissions related to respiratory adverse events |
6-months post treatment
|
|
The 6-minute walk tests
Aikaikkuna: 6-months post treatment
|
The 6-minute walk tests |
6-months post treatment
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Microvesicle quantification
Aikaikkuna: 6-months post treatment
|
Microvesicle quantification |
6-months post treatment
|
|
Lobar volumes and gas trapping as determined by quantitative CT and parametric response mapping
Aikaikkuna: 6-months post treatment
|
Lobar volumes and gas trapping as determined by quantitative CT and parametric response mapping |
6-months post treatment
|
|
Small airways function as assessed by Impulse Oscillometry (IOS)
Aikaikkuna: 6-months post treatment
|
Small airways function as assessed by Impulse Oscillometry (IOS) |
6-months post treatment
|
|
Composition of epithelial ultrastructure as assessed by transmission electron microscopy
Aikaikkuna: 6-months post treatment
|
Composition of epithelial ultrastructure as assessed by transmission electron microscopy |
6-months post treatment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Pallav Shah, MD, The Royal Brompton Hospital
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Krooninen sairaus
- Sairauden ominaisuudet
- Hengitysteiden infektiot
- Infektiot
- Hengityselinten sairaudet
- Keuhkosairaudet
- Keuhkoputken sairaudet
- Keuhkosairaudet, obstruktiiviset
- Keuhkoputkentulehdus
- Patologiset tilat, merkit ja oireet
- Keuhkosairaus, krooninen obstruktiivinen
- Keuhkoputkentulehdus, krooninen
- salikyylihydroksaamihappo
Muut tutkimustunnusnumerot
- 022
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .